This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Structuring patient assistance programs as independent non-profit foundations helps pharmaceuticalcompanies reduce regulatory and legal exposure while allowing for more holistic, patient-centered support. Lastly, PAPs that are directly managed by pharmaceuticalcompanies may also struggle with public image issues.
Omnichannel Marketing Strategies Omnichannel marketing ensures consistency across all platforms—whether it’s an email, social media post, or in-person event. By 2025, pharmaceuticalcompanies will need to adapt and innovate to remain competitive and effectively reach their target audiences.
Optimizing ROI with Multichannel Approaches Using multiple channels—email, social media, in-person events—ensures no opportunity is missed. Healthcare marketing bridges the gap between pharmaceuticalcompanies and their audience, enhancing brand awareness and trust. How can digital marketing benefit pharmaceuticalcompanies?
Common brand-name drugs that contain this ingredient include Ozempic , Wegovy , and Rybelsus all manufactured by Novo Nordisk, a Danish pharmaceuticalcompany. Ozempic and Wegovy are also used to reduce the risk of major cardiovascular events. So how do you know which one you have?
In the digital-first era, social media marketing strategies are reshaping how pharmaceuticalcompanies engage with healthcare professionals, patients, and caregivers. Social media marketing strategies in this sector depend on a deep understanding of FDA guidance, adverse event reporting, and promotional labeling limits.
Disease awareness campaigns can also reach specific patient groups based on demographics and interests, helping pharmaceuticalcompanies create more personalized outreach. Paid campaigns on Twitter can be effective for event promotions, conference participation, and patient advocacy initiatives. In the U.S.,
This rapid processing not only enhances throughput, but will also allow pharmaceuticalcompanies to respond more swiftly to market demands. DMC’s innovative design incorporates an ultrathin conductive layer, typically made of gold, which enables the application of electrical fields across ionic and affinity membrane adsorbers.
Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercialization Leadership Manufacturing Patient Pharma Policy & Regulation Research & Development Library Events Press Releases PharmaVoice 100 Nominate 2024 PV100 2023 PV100 Sign up Search Sign up Search An article from Q&A Need a DTC platform?
Bridging the Gap Between Strategy and Practice in IDN Partnerships Partha Anbil ; Kamini Anbil June 9th 2025 Article In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceuticalcompanies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).
This is progressing through a phase 3 trial and includes comparator arms with standard-of-care treatments like daratumumab, bortezomib (Velcade; Millennium/Takeda and Janssen PharmaceuticalCompanies), and lenalidomide. 2 We’re still trying to figure out where these new treatments best fit.
AI-driven algorithms can predict optimal doses and identify patients at risk of adverse events, enabling dynamic adjustments in therapy. For example, personalised dosing strategies for poly (ADP-ribose) polymerase inhibitors have been proposed based on DNA damage repair pathway alterations observed through NGS.
These tools reveal which digital assets—such as unbranded disease awareness pages or branded landing pages—contribute most to conversion events like doctor visits or prescription fills. These technologies allow for real-time bidding, predictive audience modeling, and performance-based optimizations that weren’t possible just a few years ago.
In 2022, based upon a complaint filed by a pharmaceuticalcompany, CMS was asked to reevaluate the SSA section that establishes the J-code,” Soefje said. So, the pharmaceuticalcompanies then pushed to get their 505(b)(2) drugs declared sole source,” Soefje said. “If This went into effect in January 2022.”
Related Content Bridging the Gap Between Strategy and Practice in IDN Partnerships Partha Anbil ; Kamini Anbil June 9th 2025 Article In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceuticalcompanies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).
Pharmaceuticalcompanies have responded with growing investment in the research and development of novel eye treatments and drug delivery systems designed to address key challenges in ocular therapy. Challener News Article Hydrogels, drug-eluting contact lenses, and other implant technologies show real promise.
Brand Authority: By appearing at the top of search engine results, pharmaceuticalcompanies increase brand credibility among HCPs. Best For: Thought leadership, industry networking, and professional event promotions. Targeting Options: Job title, seniority, skills, company size, and industry.
Large pharmaceuticalcompanies such as AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications, accounting for 63% of licensing deals between 2021 and 2025 year-to-date. ASOs accounted for more than half ($3.54 billion), while siRNAs made up more than a third ($2.51
24 Hours in the Hub Still Matters More June 16, 2025 By Chris Dowd, ConnectiveRx Commentary Article Pharmaceutical Commerce Pharmaceutical Commerce - June 2025 Volume 20 Issue 3 Doubling down on patient access and support fundamentals will win out over Washington’s next move.
The platform provides a means of technical exchange on high-quality, ready-to-fill primary packaging between pharmaceuticalcompanies, contract manufacturers, and contract development and manufacturing organizations.
Some are also approved to help lower the risk of heart disease and cardiovascular events in people with diabetes or obesity. Novo Nordisk is the only pharmaceuticalcompany that makes FDA-approved medications containing semaglutide. Semaglutide is available in oral and injection form.
Medical affairs is the bridge between pharmaceuticalcompanies and healthcare providers. Theres also pharmacovigilance, where experts analyze medication safety and adverse events. He had the qualifications, but he wasnt getting the traction he needed. The problem wasnt his knowledge; it was his approach.
More specifically, the Indian Pharmaceutical Alliance, an organisation representing the country’s largest pharmaceuticalcompanies, has urged the government to reduce import tariffs from the current 10% to zero for pharmaceutical imports from the US.
” How AI Will Revolutionize Medical Affairs Pharmaceuticalcompanies are actively leveraging artificial intelligence and its capabilities, encouraging their medical affairs teams to make AI a critical part of their workflows.
Zentiva Group has entered into a licence and supply agreement with pharmaceuticalcompany Lupin for the commercialisation of the latter’s biosimilar Certolizumab Pegol, a tumour necrosis factor alpha (TNFα) inhibitor medicine, across several markets. Credit: Zentiva Group, a.s.
Jacqueline Durett Few times in the evolution of a pharmaceuticalcompany are as exciting as during the flurry of launch readiness activities focused on bringing a new drug to market. All buzz-building activities must align with applicable government regulations and internal company policies.
This report looks at marketed therapies and their sales projections, pipeline drug trends, and key development challenges for pharmaceuticalcompanies, as well as the role of CDMOs in targeted modality development and what to look for in a development and manufacturing partner. You will receive an email shortly.
Being that TekniPlex Healthcare is indirectly involved with self-injectable devices, their prominence has brought various challenges for pharmaceuticalcompanies to overcome, including the evolution of meds. The industry is evolving, and the success of drugs in new formats is paving the way for innovation across the board. “To
Leading parenteral packaging provider Datwyler, for example, operates its FirstLine® manufacturing facilities across North America, Europe, and Asia, enabling pharmaceuticalcompanies to procure stoppers and plungers that meet the same high standards from around the world.
The government therefore is advocating for the creation of the new drug regulatory agency to expedite economic growth, streamline drug approvals and attract international pharmaceuticalcompanies to invest in the country.
Compounded semaglutide is made by special compounding pharmacies rather than pharmaceuticalcompanies. The medication is available in both brand-name and compounded forms, although the compounded forms are not FDA approved. A monthly supply of semaglutide ranges from about $129$1,850 without insurance. mL of 5 mg/0.5 mL of 5 mg/0.5
In one of the fierier remarks from the roundtable, RFK Jr said: “At every level, doctors, other providers, our hospitals, the pharmaceuticalcompanies, the insurance companies, all make money by keeping us sick. We need to fundamentally change that so that we are focusing on curing disease and making people better.”
It feels like in the US, pharmaceuticalcompanies are capitalising on people’s frustration and desperation to lose weight.” Compounded GLP-1RAs have completely disrupted pricing frameworks for Wegovy and Mounjaro, what happens now? “I
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content